IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Confirmation No. 4199 In re Patent Application of **HAYNES** et al Atty. Ref.: 01579-1093 Group: 1648 Serial No. 10/572,638 Examiner: Parkin, J.S. Filed: December 22, 2006 For: CONSENSUS/ANCESTRAL IMMUNOGENS Commissioner for Patents April 4, 2011 P.O. Box 1450 Alexandria, VA 22313-1450 Sir: INFORMATION DISCLOSURE STATEMENT M 1. PTO/SB/08a Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits] N/C 2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C Fee Payment Pursuant to 37 CFR 1.97(c) 2 .(b) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00 3. Pursuant to 37 CFR 1.97(d) lafter Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00 The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98: \boxtimes A list of documents on Form PTO/SB/08a together with copies (as may be required) of each identified document and a translation or a

concise explanation of each non-English language document (such

as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action] 冈 5. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; \Box 6. and The required Statement made in item 8 below; or a) b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) 7. Statement and Rule 17(p) fee), but before final fee payment]; and The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; a) and b) The required Statement is stated in item 8 below. 8. Statement under 37 CFR 1.97(e) The undersigned attorney of record hereby certifies uncer 37 C.F.R. a) §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or No item of information contained in this Information Disclosure Statement b) was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

Ву:

Mary J. Wilson Reg. No. 32,955

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100